Nanoveu Limited prepares U.S. OTCQB listing to expand access to EMASS and Eyefly3D investors

Nanoveu Limited (ASX: NVU) announced on June 17, 2025, that it has initiated the process to dual-list its ordinary shares on the U.S. OTCQB Market, in a move designed to broaden its international shareholder base and increase visibility for its proprietary semiconductor and 3D display platforms. The Australian technology innovator said the U.S. listing is targeted for completion in the third quarter of calendar year 2025, offering domestic investors in North America an easier path to engage with Nanoveu Limited’s microcap equity.

Headquartered in Perth, Western Australia, Nanoveu Limited is best known for three technology platforms: its ultra-low-power EMASS system-on-chip architecture, the Eyefly3D nano-lens display solution, and the Nanoshield antiviral polymer film. Each of these products supports high-value use cases in edge AI computation, glasses-free content visualisation, and self-disinfecting surfaces, respectively. The dual-listing strategy is positioned as a key pillar in the group’s global commercialisation effort, particularly targeting advanced technology markets and device partners in the United States.

What does Nanoveu Limited’s OTCQB listing mean for North American investor participation?

Nanoveu Limited stated that the OTCQB listing would provide U.S.-based investors with streamlined, dollar-denominated access to NVU shares, allowing trades to occur during local U.S. market hours. The move is designed to remove cross-border friction in retail and institutional participation, especially for investors focused on emerging technologies such as edge computing and augmented reality displays.

Executives noted that this dual listing will operate in parallel with Nanoveu Limited’s primary ASX listing and will not introduce material compliance burdens due to existing adherence to Australian regulatory standards. The OTCQB platform, operated by OTC Markets Group, is recognised as a cost-effective entry point for foreign issuers looking to engage the U.S. capital markets. Nanoveu Limited’s eligibility benefits from its current ASX disclosure regime, which satisfies the OTCQB requirements under the U.S. Securities and Exchange Commission’s foreign issuer exemptions.

Institutional sentiment toward Australian technology microcaps in the U.S. has historically remained cautious due to limited liquidity and transparency. By establishing a U.S. listing, Nanoveu Limited hopes to signal long-term intent and encourage early-stage analyst tracking. Sources familiar with similar dual listings have suggested that such a move often improves valuation multiples by increasing trading volumes and brand visibility.

How does Nanoveu Limited plan to leverage the listing to commercialise its EMASS semiconductor platform?

The EMASS platform, developed under Nanoveu Limited’s wholly owned subsidiary Embedded Ai Systems Pte Ltd, is central to the company’s ambition to disrupt power-constrained edge AI applications. Built on a RISC-V architecture, the EMASS system-on-chip (SoC) includes custom AI accelerators capable of processing millions of neural network parameters at microwatt-level power consumption.

The ultra-low power profile positions EMASS as a viable solution for next-generation wearable medical sensors, IoT endpoints, drones, and augmented or virtual reality devices. The SoC is designed for always-on processing, real-time anomaly detection, and secure data handling—critical features in decentralized health and biometric applications.

Mark Goranson, Chief Executive of Nanoveu Limited’s semiconductor division, stated that EMASS was “engineered to solve one of the industry’s hardest constraints: bringing meaningful AI to the edge with near-zero energy overhead.” He added that an OTCQB listing would bolster Nanoveu Limited’s ability to attract device manufacturers, R&D partnerships, and strategic licensing discussions in the U.S., where interest in sovereign, energy-efficient AI hardware is accelerating due to rising demand in defense, wearables, and consumer electronics.

Industry analysts tracking edge AI architecture suggest that platforms like EMASS could fill key gaps where NVIDIA or Qualcomm’s solutions are either overpowered or overly expensive. As of mid-2025, demand for sovereign, RISC-V-based architectures in constrained compute environments is growing rapidly in the U.S., aided by policy interest in low-energy silicon ecosystems.

What opportunity does Nanoveu Limited see for its Eyefly3D and Nanoshield platforms in the U.S. market?

Beyond its semiconductor ambitions, Nanoveu Limited is positioning Eyefly3D and Nanoshield as commercial enablers in the consumer technology and materials innovation segments. Eyefly3D is a hardware-software platform that transforms ordinary smartphone and tablet screens into immersive 3D displays without requiring external glasses. The product includes a nano-imprinted film that overlays devices and works in conjunction with AI-driven real-time 2D-to-3D conversion software.

Applications span digital signage, educational media, retail displays, and medical imaging. The U.S. market, which has seen renewed interest in glasses-free AR and visualisation tools amid growing investments in spatial computing, represents a high-priority expansion zone.

Separately, the Nanoshield product line—comprising transparent, self-disinfecting polymer films with embedded Cuprous nanoparticles—has continued to gain traction as industries seek surface-based antimicrobial solutions. Variants such as Nanoshield Marine and Nanoshield Solar have been developed to protect ship hulls from aquatic growth and to maintain the cleanliness of photovoltaic surfaces, respectively.

The dual listing could provide Nanoveu Limited with a platform to secure broader licensing partnerships and government-led innovation trials in the U.S., where institutional demand for novel materials science applications remains strong.

What financial position and share performance underpin Nanoveu Limited’s current market outlook?

As of June 18, 2025, Nanoveu Limited (ASX: NVU) was trading at AUD 0.039, reflecting a 12-month return of 69.57 percent. The company has 866.03 million ordinary shares on issue, giving it a market capitalisation of AUD 33.78 million. Trading volumes remain relatively modest, with 3.6 million shares exchanged on the most recent trading day, but analysts note that OTCQB exposure could support greater liquidity over time.

The company ranks 119th out of 247 in the ASX technology sector and 1,329th out of 2,324 across the broader exchange. Despite its microcap status, investor interest has increased following consistent technical updates on the EMASS platform and growing awareness of its dual-market product roadmap.

Nanoveu Limited has not disclosed its latest revenue figures in the June 17 announcement, nor has it released earnings guidance, but it continues to describe the EMASS and Eyefly3D rollouts as “development acceleration” priorities. Investors continue to monitor the company’s cash runway and commercialization timelines, particularly as the group moves toward securing integration partnerships with North American device makers.

What future developments are expected following the completion of Nanoveu’s dual listing?

Once listed on the OTCQB platform, Nanoveu Limited will be eligible to attract U.S.-based institutional investors who may otherwise be unable to trade ASX-listed equities directly. The company also believes the listing could serve as a launchpad for future upgrades to a major U.S. exchange such as NASDAQ, depending on capitalisation growth and governance alignment.

Managing Director Alfred Chong commented that “pursuing an OTCQB listing marks an important milestone as we expand Nanoveu Limited’s footprint into the world’s largest capital market.” He emphasized that the dual listing is part of a broader effort to elevate the company’s status as a global technology brand at the intersection of AI, nanomaterials, and immersive displays.

No further timelines have been provided beyond the CYQ3 2025 target for the OTCQB debut. However, market observers expect Nanoveu Limited to accelerate communications and potentially launch investor-facing briefings to accompany its U.S. entry.